Document 0195
 DOCN  M9580195
 TI    A comparison of zidovudine, didanosine, zalcitabine and no
       antiretroviral therapy in patients with advanced HIV disease.
 DT    9506
 AU    Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD;
       George NJ; Britton DJ; AIDS Center, St Vincent's Hospital and Medical
       Center of New; York, NY 10011, USA.
 SO    Int J STD AIDS. 1995 Jan-Feb;6(1):19-26. Unique Identifier : AIDSLINE
       MED/95244659
 AB    Three nucleoside analogues, zidovudine (AZT), didanosine (ddI), and
       zalcitabine (ddC), are approved for use in the treatment of patients
       with HIV infection. This retrospective study compares the 3 drugs and
       examines the overall utility of antiretroviral therapy by way of
       comparisons to a no treatment (No Rx) group in patients with advanced
       HIV disease. Patients with advanced HIV disease were enrolled in
       didanosine (August 1989-December 1990) or zalcitabine (October
       1990-February 1992) expanded access programmes; continued on zidovudine
       treatment despite fulfilling criteria for zidovudine failure or
       intolerance; or maintained on no antiretroviral treatment. Statistical
       analysis revealed that patients on nucleoside analogue therapy had fewer
       opportunistic infections (P = 0.001) than those who received no
       antiretroviral treatment. The Kaplan-Meier 12-month estimate of survival
       was significantly longer among patients who switched from zidovudine to
       zalcitabine but not among patients who switched to didanosine, when
       compared to the other 2 groups (P = 0.05).
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY  Adult
       Aged  Comparative Study  Didanosine/ADVERSE EFFECTS/*THERAPEUTIC USE
       Female  Follow-Up Studies  Human  Male  Middle Age  Retrospective
       Studies  Support, Non-U.S. Gov't  Survival Analysis  Zalcitabine/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Zidovudine/ADVERSE EFFECTS/*THERAPEUTIC USE
       CLINICAL TRIAL  CONTROLLED CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).